Ryan R. Willard

Catalytic in vivo protein knockdown by small-molecule PROTACs

Daniel P. Bondeson, Alina Mares, Ian E. Smith et al. · Nature Chemical Biology · 2015 · 1.3K citations · Full text

Biochemistry, Protein Assembly, Natural Sciences +2

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

Jemilat Salami, Shanique Alabi, Ryan R. Willard et al. · Communications Biology · 2018 · 334 citations · Full text

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Journal of Clinical Oncology · 2019 · 199 citations

Androgen Receptor, Tumor Biology, Molecular Pharmacology +21

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 130 citations

Breast Oncology, Estrogen Receptor, Gynecology +20

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 120 citations · Full text